ClinicalTrials.gg
CompletedNCT05781399Updated Jul 16, 2026

First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

A Phase 1/2 interventional study of JNT-517 Suspension and Placebo Suspension in Phenylketonuria, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 15 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2026.
  • Registered 3 months after the study started (first participant enrolled Oct 2022, registered Feb 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
163
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies in Phenylketonurias with a site in United States — 16 open to participants now, 21 under way, 4 of them phase 3. Phenylketonurias · United States.

Enrollment
9th of 63
163 · median 33
Started
2022
with 5 others
Phase 1/2
8 of 93
1 open now
Registered
75th of 93
by date
Lead sponsor
5 of 93
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 93 studies in Phenylketonurias with a site in United States, this one is the 9th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2022, is one of 8 in phase 1/2, and was the 75th registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

16 of the 93 studies in Phenylketonurias with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies in Phenylketonurias with a site in United States, or all of them as a file.
02

Study summary

The goal of Parts A and B of this Phase 1/2, first-in-human, randomized study is to assess the safety, tolerability, and pharmacokinetics (PK) of single (SAD) and multiple (MAD) ascending doses of oral JNT-517 in healthy participants. In Part C, the goal is to evaluate the differences in bioavailability between a tablet and suspension formulation of JNT-517 and the food effect in healthy volunteers. All participants in Part C will receive JNT-517. The goal of Part D is to assess the safety, tolerability, PK, and effect on urinary Phe and other amino acids of JNT-517 in participants with phenylketonuria (PKU). Participants in Part D will receive either JNT-517 or placebo and will be blinded to their treatment assignment.

The study consists of 6 parts:

  • Part A: SAD in healthy participants -randomized, double-blind, placebo-controlled
  • Part B: MAD in healthy participants (14 days)-randomized, double-blind, placebo-controlled
  • Part C: Relative bioavailability of 2 formulations and food effect in healthy participants-randomized, open-label
  • Part D: Phase 2 in participants with PKU (4 weeks)-randomized, double-blind, placebo-controlled
  • Part E: Phase 2 in participants with PKU (4 weeks) open label
  • Part F: SAD Phase 1 in healthy participants, randomized, double-blind, placebo-controlled

In each part, participants will complete a Screening Period, a Treatment Period, and a Follow-up Period for safety.

03

Conditions studied

  • Phenylketonuria

Browse trials for

Keywords

  • PKU
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Parts A, B, C, and F:

  1. Males and females 18 to 55 years of age.
  2. Medically healthy with no medical history.
  3. (BMI) of 18-40 kg/m2 and total body weight >50 kg (110 lbs).
  4. Non-smoker for at least 2 weeks prior to dosing and willing to abstain during the study.

    Part D and E:

  5. Males and females 18 to 65 years of age, inclusive.
  6. Diagnosis of PKU with a confirmed genotype.
  7. At least 2 plasma Phe levels >600 μM over the past 12 months.
  8. BMI of 18-40 kg/m2.

    All Parts:

  9. Females of must agree to use 2 highly effective methods.
  10. Capable of giving signed and able to comply with study procedures.

Key Exclusion Criteria:

All Parts:

  1. Any acute or chronic medical condition that would prevent the participant from complying with the procedures or place the participant at risk if they participate in the study.
  2. Positive for or C or .
  3. Any history of in the last 5 years, excluding non-melanoma skin cancer.
  4. Any history of liver disease.
  5. Any surgical or medical conditions that may affect study drug absorption, distribution, metabolism, or excretion.
  6. Participation in another drug trial within 30 days or, if known, 5 half-lives of the investigational drug (whichever is longer).
  7. History of drug/alcohol abuse in the last year.
  8. Current, recent, or suspected infection within 4 weeks of Screening of SARS-CoV-2/COVID-19.
  9. Received a vaccine for SARS-CoV-2/COVID-19 within 14 days of Screening.
  10. Unable to tolerate oral medication.
  11. Allergy to JNT-517 or any component of the investigational product.
  12. Received >50 mL of blood or plasma within 30 days of Screening or >500 mL of blood or plasma within 60 days of Screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
163 participants (actual)

Study arms

  • Experimental
    JNT-517 SAD (Part A and Part F)

    Single dose of JNT-517 or placebo in fasted state.

    Drug: JNT-517 Suspension · Drug: Placebo Suspension

  • Experimental
    JNT-517 MAD (Part B)

    JNT-517 or placebo once or twice daily for 14 days, with first daily dose given after an overnight fast.

    Drug: JNT-517 Suspension · Drug: Placebo Suspension

  • Experimental
    JNT-517 Suspension Then Tablet Fasted Then Tablet Fed (Part C)

    Single dose of JNT-517 suspension, JNT-517 tablet in a fasted state, and JNT-517 tablet in a fed state in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.

    Drug: JNT-517 Suspension · Drug: JNT-517 Tablet

  • Experimental
    JNT-517 Tablet Fasted Then Tablet Fed Then Suspension (Part C)

    Single dose of JNT-517 tablet in a fasted state, JNT-517 tablet in a fed state, and JNT-517 suspension in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.

    Drug: JNT-517 Suspension · Drug: JNT-517 Tablet

  • Experimental
    JNT-517 Tablet Fed Then Suspension Then Tablet Fasted (Part C)

    Single dose of JNT-517 tablet in a fed state, JNT-517 suspension, and JNT-517 tablet in a fasted state in a sequential, open-label manner. Each treatment is separated by a minimum of 5 half-lives.

    Drug: JNT-517 Suspension · Drug: JNT-517 Tablet

  • Experimental
    JNT-517 PKU (Part D and E)

    JNT-517 or placebo daily for 4 weeks. Dose is based on data from Parts A, B, and C.

    Drug: JNT-517 Tablet · Drug: Placebo Tablet

Interventions

  • JNT-517 in on-site compounded suspension

  • DrugPlacebo Suspension

    On-site compounded placebo suspension

  • JNT-517 tablets, 25 mg and 75 mg

  • DrugPlacebo Tablet

    Matching film-coated placebo tablet

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events

    Reported based on results of 12-lead ECGs, vital signs, clinical laboratory tests, and other medical assessments.

    Time frame: Parts A/C/F: Screening to Day 8; Part B: Screening to Day 21; Part D/E: Screening to Day 35

Secondary outcomes

  1. Plasma area under the concentration-time curve (AUC) of JNT-517

    Time frame: Parts A/C/F: pre-dose to 72 hrs post-dose on Day 1; Part B: pre-dose to 24 hrs post-dose on Days 1, 14 and pre-dose on Days 3, 13; Part D/E: pre-dose to 4 hrs post-dose on Days 1, 14, 28

  2. Maximum observed plasma concentration (Cmax) of JNT-517

    Time frame: Parts A/C/F: pre-dose to 72 hrs post-dose on Day 1; Part B: pre-dose to 24 hrs post-dose on Days 1, 14 and pre-dose on Days 3, 13; Part D/E: pre-dose to 4 hrs post-dose on Days 1, 14, 28

  3. Time to maximum plasma concentration (Tmax) of JNT-517

    Time frame: Parts A/C/F: pre-dose to 72 hrs post-dose on Day 1; Part B: pre-dose to 24 hrs post-dose on Days 1, 14 and pre-dose on Days 3, 13; Part D/E: pre-dose to 4 hrs post-dose on Days 1, 14, 28

  4. Plasma terminal half-life (t1/2) of JNT-517

    Time frame: Parts A/C/F: pre-dose to 72 hrs post-dose on Day 1; Part B: pre-dose to 24 hrs post-dose on Days 1, 14 and pre-dose on Days 3, 13; Part D/E: pre-dose to 4 hrs post-dose on Days 1, 14, 28

  5. Comparison of Tmax of JNT-517 in fed and fasted states

    Part C only

    Time frame: Pre-dose to 72 hrs post-dose on Day 1

  6. Comparison of Cmax of JNT-517 in fed and fasted states

    Part C only

    Time frame: Pre-dose to 72 hrs post-dose on Day 1

  7. Comparison of AUC of JNT-517 in fed and fasted states

    Part C only

    Time frame: Pre-dose to 72 hrs post-dose on Day 1

  8. Changes in urinary amino acid levels

    Part D/E only. Urine samples will be collected at the indicated timepoints and analyzed for amino acid levels, including Phe.

    Time frame: Screening and Days 1, 7, 14, 21, 28

07

Study locations

15 sites
  • University of Florida College of Medicine
    Gainesville, Florida 32610, United States
  • University of South Florida
    Tampa, Florida 33620, United States
  • Rare Disease Research
    Atlanta, Georgia 30329, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Oregon Health & Sciences University
    Portland, Oregon 97239, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Utah Health - The University of Utah Hospital
    Salt Lake City, Utah 84112, United States
  • Nucleus Network Melbourne
    Melbourne, Melbourne VIC 3004, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Mater Misericordia Ltd
    South Brisbane, Queensland 4101, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Jul 2025, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2023
First posted
Mar 23, 2023
StartActual
Oct 31, 2022
Primary completionActual
Jul 29, 2025
CompletionActual
Jul 29, 2025
Results delay requested
Jul 2, 2026
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05781399
Responsible party
Sponsor
First posted
Mar 23, 2023
Start date
Oct 31, 2022
Primary completion
Jul 29, 2025
Completion
Jul 29, 2025
Last update
Jul 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Repinatrabit

Start the discussion